Melanoma Clinical Trial
Official title:
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Verified date | May 2020 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
Exome sequencing can identify certain gene mutations in a person's tumor. This can then be
used to create cancer treatments. In this study, researchers will make a treatment called a
messenger ribonucleic acid (mRNA) vaccine. The vaccine might cause certain tumors to shrink.
Objective:
To see if the mRNA vaccine is safe and can cause metastatic melanoma or epithelial tumors to
shrink.
Eligibility:
People 18-70 years old with metastatic melanoma or epithelial cancer
Design:
Participants will be screened under protocol 99-C-0128.
Participants will provide samples under protocol 03-C-0277:
Participants will provide a piece of their tumor from a previous surgery or biopsy.
Participants will have leukapheresis: Blood is removed through a needle in one arm and
circulated through a machine that takes out the white blood cells. The blood is then returned
through a needle in the other arm.
Participants will have many tests:
Scans and x-rays
Heart and lung function tests
Blood and urine tests
Participants will receive the mRNA vaccine every 2 weeks for up to 8 weeks. They will get the
vaccine as an injection into the upper arm or thigh. They may receive a second course of
vaccines if the study doctor determines it is needed.
Participants will have follow-up visits approximately 2 weeks after their final vaccine, then
1 month later, then every 1-2 months for the first year, and then once a year for up to 5
years. Each visit may take up to 2 days and include:
Physical exam
Blood tests
Scans
Leukapheresis at the first visit
Status | Terminated |
Enrollment | 5 |
Est. completion date | November 5, 2019 |
Est. primary completion date | June 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
- INCLUSION CRITERIA: - Measurable (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria), metastatic melanoma, gastrointestinal, or genitourinary cancer with at least one lesion that is resectable. Only patients with metastatic gastrointestinal cancer will be eligible for enrollment on the Phase I portion of the study. Patients with metastatic melanoma, gastrointestinal, or genitourinary cancer will be eligible for enrollment on the Phase II portion of the study. - Confirmation of diagnosis of metastatic cancer by the National Cancer Institute (NCI) Laboratory of Pathology. - Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible. - Prior therapy with at least one first-line standard of care treatment or second-line treatment of proven effectiveness. Patients must have progressive disease after prior treatment. Prior first-or second-line treatments would include the following: - Patients with metastatic melanoma: Receipt of a checkpoint inhibitor as first-line therapy - Patients with metastatic melanoma with an activating mutation of KIT: Receipt of Imatinib - Patients with a BRAF V600 activating mutation: Receipt of appropriate targeted therapy - Patients with metastatic gastrointestinal cancer: Receipt of up to two forms of approved first- and/or second-line chemotherapy regimens - Patients with metastatic genitourinary cancers: Receipt of a first- or second-line therapy appropriate for their histologic subtype - Age greater than or equal to 18 years and less than or equal to 70 years. - Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1. - Serology - Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.) - Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by reverse transcription polymerase chain reaction (RT-PCR) and be hepatitis C virus (HCV) ribonucleic acid (RNA) negative. - Hematology - Absolute neutrophil count (ANC) > 1000/mm(3) without the support of growth factors. - White blood cell (WBC) greater than or equal to 3000/mm(3) - Platelet count greater than or equal to 100.000/mm(3) - Hemoglobin > 8.0 g/dl. Subjects may be transfused to reach this cut-off. - Chemistry - Serum Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) less than or equal to 5.0 times upper limit of normal (ULN) - Serum creatinine <1.5 times ULN or measured creatinine clearance (calculated using Cockcroft-Gault formula) > 40 ml/min - Total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's Syndrome, who must have a total bilirubin < 3.0 mg/dl. - More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the immunization regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). - Ability of subject to understand and the willingness to sign a written informed consent document. - Subjects must be co-enrolled on protocol 03-C-0277. EXCLUSION CRITERIA: - Pregnant or breastfeeding women who do not consent to stop breast-feeding while on study treatment and for 30 days after the use of the investigational vaccine where pregnancy is confirmed by a positive, rising human chorionic gonadotropin (hCG) laboratory test. - Women of child-bearing potential, defined as all women capable of becoming pregnant, unless they agree to use an appropriate method of contraception during dosing and for 120 days after the last dose (i.e., final vaccine). Effective contraception methods include a combination of any two of the following (unless method is abstinence or sterilization, in which only one method is required): - Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%). In case of use of oral contraception, women should have been stable on the same pill for a minimum of 6 months before taking study treatment. - Placement of an intrauterine device or intrauterine system. - Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository. - Total abstinence - Female sterilization at least eight weeks before taking study treatment. - Male sterilization (at least six months prior to screening). - Sexually active males must use a condom during intercourse during dosing and for 120 days after the last dose (i.e., final vaccine), and should not father a child in this period. - Any systemic steroid therapy or other form of immunosuppressive therapy within 7 days of the first dose of the vaccine. A physiologic dose of systemic corticosteroids may be approved. Inhaled or topical steroids, and less than or equal to 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. - Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses of the cardiovascular, respiratory, or immune system. - Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease). - Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities). - Any vaccinations four weeks prior to the first vaccination cycle or live vaccines at any time during the study. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Abramson J, Giraud M, Benoist C, Mathis D. Aire's partners in the molecular control of immunological tolerance. Cell. 2010 Jan 8;140(1):123-35. doi: 10.1016/j.cell.2009.12.030. — View Citation
Bos R, Marquardt KL, Cheung J, Sherman LA. Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology. 2012 Nov 1;1(8):1239-1247. — View Citation
Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol. 2009 Dec;9(12):833-44. doi: 10.1038/nri2669. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of Participants With Non-Serious Adverse Events Regardless of Attribution | Here is the count of participants with non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. | Date treatment consent signed to date off study, approximately 11 months and 4 days. | |
Other | Number of Dose Limiting Toxicities (DLT) | A DLT is all Grade 3 or greater toxicities related to the messenger ribonucleic acid vaccine with exception of Grade 3 fever, Grade 3 pruritic/itching, Grade 3 fatigue, Grade 3 metabolic laboratory abnormalities without significant clinical sequela that resolves to Grade 2 or less within 7 days, Grade 3 autoimmune toxicity that resolves to Grade 2 or less in 7 days and events that are clearly related to the patient's disease. | Up to 21 days after the first vaccination | |
Other | Maximum Tolerated Dose (MTD | A MTD is the highest dose at which =1 of 6 patient's experienced a dose limiting toxicity (i.e., All Grade 3 or greater toxicities related to the messenger ribonucleic acid vaccine with exception of Grade 3 fever, Grade 3 pruritic/itching, Grade 3 fatigue, Grade 3 metabolic laboratory abnormalities without significant clinical sequela that resolves to Grade 2 or less within 7 days, Grade 3 autoimmune toxicity that resolves to Grade 2 or less in 7 days and events that are clearly related to the patient's disease.) or the highest dose level studied if DLT's are not observed at any of the dose levels. | Up to 21 days after the first vaccination | |
Primary | Number of Participants Who Had a Clinical Response (Complete Response + Partial Response) to Treatment (Objective Tumor Regression) | Clinical response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. | up to 12 months | |
Primary | Number of Non-Serious Adverse Events Probably Related to Treatment | Here is the number of non-serious adverse events probably related to treatment assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | During treatment and up to 30 days after the first follow- up evaluation (at the second follow-up evaluation) | |
Secondary | Number of Participants With an Increase in the Quantity and Quality of Circulating Antigen-specific T Cells | Participants blood samples were assessed by fluorescence-activated cell sorting (FACS), enzyme-linked immune absorbent (ELISA)-spot and human soluble cluster of differentiation 137 (CD137) (4-1BB) upregulation assays. Differences of 2-3 fold in these assays over the baseline measures are indicative of true biologic difference. | Approximately 2 weeks after last vaccine |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|